Skip to main content
main-content

Expert opinion

09-10-2019 | Non-small-cell lung cancer | Editorial | Article

Current therapies for advanced NSCLC: The role of maintenance therapy in an immunotherapy world

Thomas Stinchcombe (Duke Cancer Institute, USA) examines the development of maintenance regimens and where they fit as immunotherapy continues to change treatment paradigms for NSCLC.

02-04-2019 | Advanced breast cancer | Editorial | Article

The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

CDK4/6 inhibitors are a valuable addition to the treatment armamentarium for HR-positive, HER2-negative advanced breast cancer, but questions about their use remain. The research team behind the Dutch Sonia study explores some of the most pressing questions.

28-01-2019 | Melanoma | Editorial | Article

IDO inhibitors in advanced melanoma: A path forward?

On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.

06-11-2018 | Immunotherapy | Editorial | Article

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

16-08-2018 | Non-small-cell lung cancer | Article

Management of EGFR mutation-positive non-small-cell lung cancer: Two steps forward, looking back

Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

02-08-2018 | Breast cancer | Editorial | Article

Developing polygenic risk scores for breast cancer

Gareth Evans (University of Manchester, UK) details how genetic advances have allowed the development of relatively cheap and clinically meaningful genetic-based scores for breast cancer risk, further heralding the shift towards precision medicine in breast cancer.

26-07-2018 | Non-small-cell lung cancer | Editorial | Article

Choosing an immunotherapy approach in patients with advanced NSCLC

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

06-07-2018 | Prostate cancer | Editorial | Article

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

02-07-2018 | Prostate cancer | Editorial | Article

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

28-06-2018 | Surgery | Editorial | Article

Breast cancer-related lymphedema management: Current state and future directions

Breast cancer-related lymphedema is a debilitating complication of breast cancer surgery. Babak Mehrara (Memorial Sloan Kettering Cancer Center, NY, USA) outlines the current state of lymphedema management and poses some questions for the future.

01-05-2018 | Obesity | View from the clinic | Article

Body fat and cancer: Why does it matter?

Elevated levels of body fat have consistently been found to be associated with increased risk of a number of cancers. In this 'View from the clinic' article Daniel Nixon (Southeastern Regional Medical Center, USA) explores this relationship and provides his perspective on how to educate and support patients.

23-04-2018 | Survivorship | Editorial | Article

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

05-02-2018 | Immunotherapy | View from the clinic | Article

Explaining immunotherapy to our patients with non-small cell lung cancer

Immunotherapy is changing practice in lung cancer, and with this, patient education. In this 'View from the clinic' article, Advisory Board member Beth Eaby-Sandy describes how she explains the new immunotherapy treatments to her patients. 

02-02-2018 | Chronic myeloid leukemia | Editorial | Article

Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

08-01-2018 | Breast cancer | Editorial | Article

New paradigm: Testing elimination of breast cancer surgery after neoadjuvant systemic therapy

Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Henry Kuerer (MD Anderson, USA) discusses the exciting recent advances in this area.

04-01-2018 | Small-cell lung cancer | Conference report | Article

Progress in small cell lung cancer: an update from the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan

Advisory Board member Fiona Blackhall discusses the major new results in small cell lung cancer presented at the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan.

19-12-2017 | Ovarian cancer | Editorial | Article

Fertility-sparing surgery in high-risk epithelial ovarian cancer: from the patients wishes to the precautionary principle

Fertility-sparing surgery is an important option for young women with ovarian cancer but there are questions surrounding its safety in all cases. Philippe Morice and Sébastien Gouy (Institut Gustave Roussy, France) discuss the problems faced in high-risk cases.

26-07-2017 | Non-small-cell lung cancer | Editorial | Article

Changing landscape of treatment for ALK-positive non-small cell lung cancer

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

28-04-2017 | Genitourinary cancers | Conference report | Article

Highlights from the 2017 Genitourinary Cancer Symposium (ASCO-GU), Orlando, Florida, USA

Advisory Board member Prof Axel Merseburger discusses the key outcomes from the 2017 ASCO-GU Congress in Orlando, Florida.

14-03-2017 | Leukemia | Editorial | Article

FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach

Advisory Board Member Xavier Thomas discusses the potential of FLT3 inhibitors for the treatment of acute myeloid leukemia.

Image Credits